US 10316038
Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
granted A61PA61P29/00
Quick answer
US patent 10316038 (Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer) held by Aclaris Therapeutics, Inc. expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Aclaris Therapeutics, Inc.
- Grant date
- Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61P, A61P29/00